{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"42","value":"24"}]}],"title":"1 yr post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"55","value":"36"}]}],"title":"2 yr post-transplant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Number of patients with disease reoccurrence at 1 and 2 years post-transplant","dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine, Melphalan \\& Post-transplant cyclophosphamide\n\nFludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;\n\nMelphalan\n\nCyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.\n\nperipheral blood stem cell transplant","id":"OG000","title":"Reduced-Intensity Mismatched Transplant"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Relapse Incidence","type":"SECONDARY","unitOfMeasure":"percentage of patients"}